secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2026-08-06T20:19:37+00:00
Accession:  0001437749-26-026282
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Puma Biotech Q2 net income $8.2M, raises 2026 guidance on NERLYNX demand
------------------------------------------------------------------------

- Q2 product revenue $53.6M (+9% YoY); GAAP net income $8.2M ($0.16/sh) vs $5.9M ($0.12/sh) in Q2 2025.
- Non-GAAP adjusted net income $10.1M ($0.20/sh basic) vs $7.5M ($0.15/sh) prior year.
- Raises FY 2026 net product revenue guidance to $205-209M (prior $202-206M); net income to $17-20M (prior $16-19M).
- Debt fully repaid in May 2026; cash & securities $93.9M at June 30, 2026.
- R&D expenses rose $9.4M YTD on alisertib trial activity; milestones include ALISCA-Lung2 initiation in Q3 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000143774926026282/0001437749-26-026282-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000143774926026282/pbyi20260608_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-026282

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer